Arch Therapeutics Performance
| ARTHDelisted Stock | USD 0.0001 0.00 0.00% |
The firm shows a Beta (market volatility) of -11.0, which signifies a somewhat significant risk relative to the market. As returns on the market increase, returns on owning Arch Therapeutics are expected to decrease by larger amounts. On the other hand, during market turmoil, Arch Therapeutics is expected to outperform it. Arch Therapeutics right now shows a risk of 0.0%. Please confirm Arch Therapeutics variance and the relationship between the treynor ratio and day median price , to decide if Arch Therapeutics will be following its price patterns.
Risk-Adjusted Performance
Weakest
Weak | Strong |
Over the last 90 days Arch Therapeutics has generated negative risk-adjusted returns adding no value to investors with long positions. Despite fairly strong basic indicators, Arch Therapeutics is not utilizing all of its potentials. The recent stock price confusion, may contribute to short-horizon losses for the traders. ...more
Arch |
Arch Therapeutics Relative Risk vs. Return Landscape
If you would invest 0.01 in Arch Therapeutics on November 8, 2025 and sell it today you would earn a total of 0.00 from holding Arch Therapeutics or generate 0.0% return on investment over 90 days. Arch Therapeutics is currently does not generate positive expected returns and assumes 0.0% risk (volatility on return distribution) over the 90 days horizon. In different words, 0% of pink sheets are less volatile than Arch, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Arch Therapeutics Target Price Odds to finish over Current Price
The tendency of Arch Pink Sheet price to converge on an average value over time is a known aspect in finance that investors have used since the beginning of the stock market for forecasting. However, many studies suggest that some traded equity instruments are consistently mispriced before traders' demand and supply correct the spread. One possible conclusion to this anomaly is that these stocks have additional risk, for which investors demand compensation in the form of extra returns.
| Current Price | Horizon | Target Price | Odds to move above the current price in 90 days |
| 0.0001 | 90 days | 0.0001 | about 72.23 |
Based on a normal probability distribution, the odds of Arch Therapeutics to move above the current price in 90 days from now is about 72.23 (This Arch Therapeutics probability density function shows the probability of Arch Pink Sheet to fall within a particular range of prices over 90 days) .
Arch Therapeutics Price Density |
| Price |
Predictive Modules for Arch Therapeutics
There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as Arch Therapeutics. Regardless of method or technology, however, to accurately forecast the pink sheet market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the pink sheet market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of Arch Therapeutics' price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Arch Therapeutics Risk Indicators
For the most part, the last 10-20 years have been a very volatile time for the stock market. Arch Therapeutics is not an exception. The market had few large corrections towards the Arch Therapeutics' value, including both sudden drops in prices as well as massive rallies. These swings have made and broken many portfolios. An investor can limit the violent swings in their portfolio by implementing a hedging strategy designed to limit downside losses. If you hold Arch Therapeutics, one way to have your portfolio be protected is to always look up for changing volatility and market elasticity of Arch Therapeutics within the framework of very fundamental risk indicators.α | Alpha over Dow Jones | 34.75 | |
β | Beta against Dow Jones | -11 | |
σ | Overall volatility | 0.08 | |
Ir | Information ratio | 0.11 |
Arch Therapeutics Alerts and Suggestions
In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of Arch Therapeutics for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for Arch Therapeutics can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.| Arch Therapeutics is not yet fully synchronised with the market data | |
| Arch Therapeutics has some characteristics of a very speculative penny stock | |
| Arch Therapeutics has a very high chance of going through financial distress in the upcoming years | |
| Arch Therapeutics currently holds 2.81 M in liabilities with Debt to Equity (D/E) ratio of 2.62, implying the company greatly relies on financing operations through barrowing. Arch Therapeutics has a current ratio of 0.8, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Debt can assist Arch Therapeutics until it has trouble settling it off, either with new capital or with free cash flow. So, Arch Therapeutics' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Arch Therapeutics sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Arch to invest in growth at high rates of return. When we think about Arch Therapeutics' use of debt, we should always consider it together with cash and equity. | |
| The entity reported the previous year's revenue of 15.65 K. Net Loss for the year was (5.28 M) with loss before overhead, payroll, taxes, and interest of (35.84 K). | |
| Arch Therapeutics currently holds about 55 K in cash with (4.46 M) of positive cash flow from operations. | |
| Roughly 15.0% of Arch Therapeutics shares are held by company insiders |
Arch Therapeutics Fundamentals Growth
Arch Pink Sheet prices reflect investors' perceptions of the future prospects and financial health of Arch Therapeutics, and Arch Therapeutics fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Arch Pink Sheet performance.
| Return On Equity | -40.15 | |||
| Return On Asset | -1.14 | |||
| Operating Margin | (364.73) % | |||
| Current Valuation | 12.54 M | |||
| Shares Outstanding | 249.94 M | |||
| Price To Earning | (16.36) X | |||
| Price To Book | 34.61 X | |||
| Price To Sales | 638.65 X | |||
| Revenue | 15.65 K | |||
| EBITDA | (4.71 M) | |||
| Cash And Equivalents | 55 K | |||
| Total Debt | 2.81 M | |||
| Debt To Equity | 2.62 % | |||
| Book Value Per Share | (0.02) X | |||
| Cash Flow From Operations | (4.46 M) | |||
| Earnings Per Share | (0.02) X | |||
| Total Asset | 2.6 M | |||
| Retained Earnings | (35.9 M) | |||
| Current Asset | 18.02 K | |||
| Current Liabilities | 3.06 K | |||
About Arch Therapeutics Performance
By evaluating Arch Therapeutics' fundamental ratios, stakeholders can gain valuable insights into Arch Therapeutics' financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Arch Therapeutics has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Arch Therapeutics has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements. Please also refer to our technical analysis and fundamental analysis pages.
Arch Therapeutics, Inc., together with its subsidiaries, operates as a biotechnology company in the United States. The company was founded in 2006 and is based in Framingham, Massachusetts. Arch Therapeutics operates under Biotechnology classification in the United States and is traded on OTC Exchange. It employs 10 people.Things to note about Arch Therapeutics performance evaluation
Checking the ongoing alerts about Arch Therapeutics for important developments is a great way to find new opportunities for your next move. Pink Sheet alerts and notifications screener for Arch Therapeutics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Arch Therapeutics is not yet fully synchronised with the market data | |
| Arch Therapeutics has some characteristics of a very speculative penny stock | |
| Arch Therapeutics has a very high chance of going through financial distress in the upcoming years | |
| Arch Therapeutics currently holds 2.81 M in liabilities with Debt to Equity (D/E) ratio of 2.62, implying the company greatly relies on financing operations through barrowing. Arch Therapeutics has a current ratio of 0.8, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Debt can assist Arch Therapeutics until it has trouble settling it off, either with new capital or with free cash flow. So, Arch Therapeutics' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Arch Therapeutics sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Arch to invest in growth at high rates of return. When we think about Arch Therapeutics' use of debt, we should always consider it together with cash and equity. | |
| The entity reported the previous year's revenue of 15.65 K. Net Loss for the year was (5.28 M) with loss before overhead, payroll, taxes, and interest of (35.84 K). | |
| Arch Therapeutics currently holds about 55 K in cash with (4.46 M) of positive cash flow from operations. | |
| Roughly 15.0% of Arch Therapeutics shares are held by company insiders |
- Analyzing Arch Therapeutics' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Arch Therapeutics' stock is overvalued or undervalued compared to its peers.
- Examining Arch Therapeutics' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Arch Therapeutics' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Arch Therapeutics' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Arch Therapeutics' pink sheet. These opinions can provide insight into Arch Therapeutics' potential for growth and whether the stock is currently undervalued or overvalued.
Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in poverty. You can also try the AI Portfolio Prophet module to use AI to generate optimal portfolios and find profitable investment opportunities.
Other Consideration for investing in Arch Pink Sheet
If you are still planning to invest in Arch Therapeutics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Arch Therapeutics' history and understand the potential risks before investing.
| Top Crypto Exchanges Search and analyze digital assets across top global cryptocurrency exchanges | |
| Commodity Channel Use Commodity Channel Index to analyze current equity momentum | |
| Price Ceiling Movement Calculate and plot Price Ceiling Movement for different equity instruments | |
| Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm | |
| Investing Opportunities Build portfolios using our predefined set of ideas and optimize them against your investing preferences | |
| Portfolio Anywhere Track or share privately all of your investments from the convenience of any device | |
| Economic Indicators Top statistical indicators that provide insights into how an economy is performing | |
| Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges | |
| Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets |